BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares.

In the most recent trading session, Nice (NICE) closed at $165, indicating a -0.6% shift from the previous trading day.

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Fourth-quarter earnings have lifted the market to all-time highs. Here are 10 stocks that Morgan Stanley is most bullish on ...

In our analysis, these 12 brokerage accounts stand out as the best choices for stock trading, due to their low fees, strong platforms and quality customer support. Many, or all, of the products ...

Decided to add this retail giant to your portfolio? Here's what you need to know before buying Amazon stock. Many, or all, of the products featured on this page are from our advertising partners ...

The S&P/ASX 200 closed 37.0 points higher, up 0.45%. Interest rate sensitives lead the Aussie stock market higher today, that ...

After reaching an all-time high of ₹516.65 per share in September, the stock has corrected by 23.15% to date. Nevertheless, it is still up 26.3% from its IPO price of ₹315. The company's ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization. Read more about EDIT and NTLA stocks here.

SLB, formerly Schlumberger, reported on Friday slightly better-than-expected fourth-quarter earnings and revenue, while increasing its quarterly dividend. Shares of SLB jumped higher early. The ...